Huang S-P, Wen Y-C, Huang S-T, Lin C-W, Wang T-D, Hsiao F-Y. Nonsteroidal anti-inflammatory drugs and risk of first hospitalization for heart failure in patients with no history of heart failure: a population-based case-crossover study. Drug Saf 2019;42:enero. [Ref.ID 103029]

Modin D, Jorgensen ME, Gislason S, Jensen JS, Kober L, Claggett B, Hegde SM, Solomon SD, Torp-Pedersen C, Biering-Sorensen T. Influenza vaccine in heart failure cumulative number of vaccinations, frequency, timing, and survival: a Danish nationwide cohort study. Circulation 2018;139:10 de diciembre. [Ref.ID 102908]

Yancy CW. Sodium restriction in heart failure: too much uncertainty — Do the trials. JAMA Intern Med 2018:5 de noviembre. [Ref.ID 102849]

The ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018;379:18 de octubre. [Ref.ID 102844]

McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, Reid CM, Lockery JE, Kirpach B, Storey E, Shah RC, Williamson JD, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin LJ, Johnston CI, Ryan J, Radziszewska B, Jelinek M, Malik M, Eaton CB, Brauer D, Cloud G, Wood EM, Mahady SE, Satterfield S, Grimm R, Murray AM, for the ASPREE Investigator Group. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med 2018;379:18 de octubre. [Ref.ID 102843]

Mahtani KR, Heneghan C, Onakpoya I, Tierney S, Aronson JK, Roberts N, Hobbs R, Nunan D. Reduced salt intake for heart failure. A systematic review. JAMA Intern Med 2018:5 de noviembre. [Ref.ID 102841]

Moore TJ, Hanzhe Z, Anderson G, Alexander C. Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015-2016. JAMA Intern Med 2018:24 de septiembre. [Ref.ID 102831]

Dahal K, Hendrani A, Sharma SP, Singireddy S, Mina G, Reddy P, Dominic P, Modi K. Aldosterone antagonist therapy and mortality in patients with ST-segment elevation myocardial infarction without heart failure. A systematic review and meta-analysis. JAMA Intern Med 2018;178:julio. [Ref.ID 102774]

Bielecka-Dabrowa A, Fabis J, Mikhailidis DP, von Haehling S, Sahebkar A, Rysz J, Banach M. Prosarcopenic effects of statins may limit their effectiveness in patients with heart failure. Trends Pharmacol Sci 2018;39:abril. [Ref.ID 102681]

Patel TK, Patel TB. Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis. Eur J Clin Pharmacol 2018;74:junio. [Ref.ID 102626]

Lopes RD, Rordorf R, De Ferrari GM, Leonardi S, Thomas L, Wojdyla DM, Ridefelt P, Lawrence JH, De Caterina R, Vinereanu D, Hanna M, Flaker G, Al-Khatib SM, Hohnloser SH, Alexander JH, Granger CB, Wallentin L, ARISTOTLE Committees and Investigators. Digoxin and mortality in patients with atrial fibrillation. J Am Coll Cardiol 2018;71:13 de marzo. [Ref.ID 102547]

Link MS. Paradigm shift for treatment of atrial fibrillation in heart failure. N Engl J Med 2018;378:1 de febrero. [Ref.ID 102521]

Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, Merkely B, Pokushalov E, Sanders P, Proff J, Schunkert H, Christ H, Vogt J, Bänsch D, for the CASTLE-AF Investigators. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378:1 de febrero. [Ref.ID 102520]

Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, Meeran K. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA 2018;319:17 de abril. [Ref.ID 102513]

Anónimo. Many lawsuits concerning diabetes drug saxagliptin transferred to US district judge in Kentucky. DIA Daily 2018:5. [Ref.ID 102461]

Miró O, Rosselló X, Gil V, Martín-Sánchez FJ, Llorens P, Herrero-Puente P, Jacob J, Bueno H, Pocock SJ, on behalf of the ICA-SEMES Research Group. Predicting 30-day mortality for patients with acute heart failure in the emergency department: a cohort study. Ann Intern Med 2017;167:698-705. [Ref.ID 102155]

Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF, for the EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017;377:28 de septiembre. [Ref.ID 102096]

Ham AC, van Dijk SC, Swart KMA, Enneman AW, van der Zwaluw NL, Brouwer-Brolsma EM, van Schoor NM, Zillikens MC, Lips P, de Groot LCPGM, Hofman A, Witkamp RF, Uitterlinden AG, Stricker BH, van der Velde N. Beta-blocker use and fall risk in older individuals: Original results from two studies with meta-analysis. Br J Clin Pharmacol 2017;83:2292-302. [Ref.ID 102082]

Ho JM-W, Macdonald EM, Luo J, Gomes T, Antoniou T, Mamdani MM, Juurlink DN. Pregabalin and heart failure: A population-based study. Pharmacoepidemiol Drug Saf 2017;26:1087-92. [Ref.ID 102064]

Grosser T, Ricciotti E, Fitzgerald GA. The cardiovascular pharmacology of nonsteroidal anti-inflammatory drugs. Trends Pharmacol Sci 2017;38:733-48. [Ref.ID 101990]